Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex®) in advanced colorectal cancer

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 987-991

  Farrugia, D C ^a   Norman, A R ^a   Cunningham, D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

5 fluorouracil; Chemotherapy; Colorectal cancer; Raltitrexed

Indexed keywords

CARMUSTINE; FLUOROURACIL; MITOMYCIN C; RALTITREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; PRIORITY JOURNAL; STOMATITIS; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINAZOLINES; SURVIVAL ANALYSIS; THIOPHENES; TREATMENT OUTCOME;

EID: 0031782749     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00017-3     Document Type: Article

References (17)

1. Jackman AL, Farrugia DC, Gibson W, et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 1995, 31A(7/8), 1277-1282.
2. ® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996, 7, 961-965.
3. Cunningham D, Zalcberg J, Smith I, et al. "Tomudex" (ZD 1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. Ann Oncol 1996, 7, 179-182.
4. Drake J.C., Allegra C.J., Moran R.G., Johnston P.G. Resistance to Tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. Biochem Pharmacol. 51:1996;1349-1355.
5. Peters GJ, Van der Wilt CL, Triest B van, et al. Thymidylate synthase and drug resistance. Eur J Cancer 1995, 31A(7/8), 1299-1305.
6. Aschele C., Sobrero A., Faderan M.A., Bertino J.R. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 51:1992;1855-1864.
7. Sobrero A.F., Aschele C., Bertino J.R. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol. 15:(1):1997;368-381.
8. Zalcberg JR, Cunningham D, Van Cutsem E, et al. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996, 14(3), 716-721.
9. Farrugia D, Cunningham D, Danenberg P, et al. A pharmacodynamic study of the thymidylate synthase inhibitor Tomudex in advanced colorectal cancer (abstract). Proc Am Assoc Cancer Res 1997, 38, 615.
10. Sorensen JM, Jordan E, Grem JL , et al. Phase I trial of ZD1694 (Tomudex), a direct inhibitor of thymidylate synthase. Ann Oncol 1994, 5(Suppl. 5), 132.
11. Harstrick A, Schleucher N, Gonzales A, et al. Interactions and cross resistance patterns between various schedules of 5-FU and the new, folate-based thymidylate synthase inhibitor Tomudex (D1694). Eur J Cancer 1995, 31A(5), S30.
12. Johnston P.G., Behan K.A., Allegra C.J., Drake J.C. Fluorouracil: active in ZD1694 (Tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels. J Natl Cancer Inst. 87:(20):1995;1558-1559.
13. Wang F.S., Achele C., Sobrero A., Chang Y.M., Bertino J.R. Decreased folylpolyglutamate synthase expression: a novel mechanism of fluorouracil resistance. Cancer Res. 53:1993;3677-3680.
14. Ross P, Norman A, Cunningham D, et al. A prospective randomised trial of protracted venous infusion (PVI) 5-FU with or without mitomycin C in advanced colorectal cancer. Br J Cancer 1997, 76(1), 32.
15. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997, 15(1), 251-260.
16. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996, 14(11), 2950-2958.
17. Conti JA, Kemeny N, Seiter K, et al. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 1994, 12(4), 695-700.